X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs CIPLA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD CIPLA LUPIN LTD/
CIPLA
 
P/E (TTM) x 20.3 45.2 44.8% View Chart
P/BV x 2.7 3.9 70.8% View Chart
Dividend Yield % 0.9 0.3 275.9%  

Financials

 LUPIN LTD   CIPLA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
CIPLA
Mar-17
LUPIN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,750622 281.4%   
Low Rs1,384458 301.9%   
Sales per share (Unadj.) Rs387.4181.9 213.0%  
Earnings per share (Unadj.) Rs56.612.9 440.0%  
Cash flow per share (Unadj.) Rs76.829.3 262.1%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.50.4 129.3%  
Book value per share (Unadj.) Rs298.9155.7 192.0%  
Shares outstanding (eoy) m451.58804.51 56.1%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x4.03.0 136.2%   
Avg P/E ratio x27.742.0 65.9%  
P/CF ratio (eoy) x20.418.4 110.7%  
Price / Book Value ratio x5.23.5 151.1%  
Dividend payout %13.215.5 85.2%   
Avg Mkt Cap Rs m707,513434,516 162.8%   
No. of employees `00016.823.0 72.9%   
Total wages/salary Rs m28,49526,338 108.2%   
Avg. sales/employee Rs Th10,418.36,349.1 164.1%   
Avg. wages/employee Rs Th1,697.01,143.0 148.5%   
Avg. net profit/employee Rs Th1,523.0449.3 338.9%   
INCOME DATA
Net Sales Rs m174,943146,302 119.6%  
Other income Rs m1,0652,287 46.6%   
Total revenues Rs m176,008148,589 118.5%   
Gross profit Rs m44,93124,758 181.5%  
Depreciation Rs m9,12213,229 69.0%   
Interest Rs m1,5251,594 95.7%   
Profit before tax Rs m35,34912,222 289.2%   
Minority Interest Rs m-720-   
Prior Period Items Rs m83-70 -118.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7851,798 544.3%   
Profit after tax Rs m25,57510,354 247.0%  
Gross profit margin %25.716.9 151.8%  
Effective tax rate %27.714.7 188.2%   
Net profit margin %14.67.1 206.6%  
BALANCE SHEET DATA
Current assets Rs m119,54287,370 136.8%   
Current liabilities Rs m61,20633,081 185.0%   
Net working cap to sales %33.337.1 89.9%  
Current ratio x2.02.6 73.9%  
Inventory Days Days7687 87.4%  
Debtors Days Days9062 144.2%  
Net fixed assets Rs m131,660111,567 118.0%   
Share capital Rs m9031,609 56.1%   
"Free" reserves Rs m134,073123,645 108.4%   
Net worth Rs m134,976125,254 107.8%   
Long term debt Rs m56,47836,454 154.9%   
Total assets Rs m266,073209,532 127.0%  
Interest coverage x24.28.7 278.9%   
Debt to equity ratio x0.40.3 143.8%  
Sales to assets ratio x0.70.7 94.2%   
Return on assets %10.25.7 178.6%  
Return on equity %18.98.3 229.2%  
Return on capital %19.38.5 226.6%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m81,88551,066 160.3%   
Fx outflow Rs m21,50617,678 121.7%   
Net fx Rs m60,37833,388 180.8%   
CASH FLOW
From Operations Rs m41,14823,824 172.7%  
From Investments Rs m-25,287-13,127 192.6%  
From Financial Activity Rs m4,332-13,239 -32.7%  
Net Cashflow Rs m20,193-2,478 -814.9%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Down; Tata Steel Top Loser(09:30 am)

Asian stocks rose in morning trade on Monday, after the US's S&P 500 extended its winning streak on Friday to six days. Markets in the Greater China region remain closed for the Lunar New Year holiday.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 19, 2018 11:47 AM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS